Chimeric Therapeutics is a cancer-fighting cell therapy company that has recently completed its phase-1A dose escalation study at the City of Hope campus in the United States. The study involved the successful treatment of a third clinical trial cohort using a scorpion venom derivative. The company's CHM 1101 (CLTX CAR T) treatment aims to treat patients with glioblastoma cancers.

Chimeric Therapeutics utilizes the first-in-class chlorotoxin (CLTX) chimeric antigen receptor (CAR) T-cell therapy, which is being developed for patients with solid tumors. This innovative treatment utilizes a 36-amino acid peptide chloride channel blocker derived from the venom of the Palestine Yellow Scorpion. The study was conducted at the renowned City of Hope's Los Angeles campus, a leading cancer research and treatment organization.

Chimeric Therapeutics is committed to advancing the development of CHM 1101 and is currently conducting a phase-1B clinical trial at the Sarah Cannon Transplant & Cellular Therapy Program in Austin, Texas. Their vision is to bring the promise of cell therapy to reality for more cancer patients by creating cellular therapies that provide permanent cures. With their groundbreaking research backed by advanced technology, Chimeric Therapeutics is revolutionizing cancer treatment